Oncternal Therapeutics, Inc.
Oncternal Therapeutics, Inc. (ONCT): 3 pipeline candidates · ~6 mo cash runway · 1 clinical trial. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
6.4 months
D/E 0.71 · 0% dilution
Lead: Phase 3
3 candidates
N/A
N/A
A transparent, data-derived signal for Oncternal Therapeutics, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$13.1M
Quarterly Burn
$7.0M
Runway
6.4 mo
Revenue
$494K
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (3 candidates)
| Drug | Phase |
|---|---|
| onct-534 | Phase 1 |
| onct-808 | Phase 1/Phase 2 |
| zilovertamab | Phase 3 |
Frequently asked questions
How many drug candidates are in Oncternal Therapeutics, Inc.'s pipeline?
Oncternal Therapeutics, Inc. (ONCT) has 3 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Oncternal Therapeutics, Inc.'s lead drug candidate?
Oncternal Therapeutics, Inc.'s most advanced tracked candidate is onct-534 (Phase 1) for Advanced castration-resistant prostate cancer (CRPC).
What is Oncternal Therapeutics, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Oncternal Therapeutics, Inc. has approximately 6.4 months of cash runway.
Who is the CEO of Oncternal Therapeutics, Inc.?
California April is the chief executive officer of Oncternal Therapeutics, Inc. (ONCT).
Get the full picture on Oncternal Therapeutics, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.